DK1368094T3 - 4-(2-Butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)-pyrazolo[1,5-a]-1,3,5-triazin, dens enantiomerer og farmaceutisk acceptable salte som corticotropin-frigivende faktor-receptor- ligander - Google Patents
4-(2-Butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)-pyrazolo[1,5-a]-1,3,5-triazin, dens enantiomerer og farmaceutisk acceptable salte som corticotropin-frigivende faktor-receptor- liganderInfo
- Publication number
- DK1368094T3 DK1368094T3 DK02713776T DK02713776T DK1368094T3 DK 1368094 T3 DK1368094 T3 DK 1368094T3 DK 02713776 T DK02713776 T DK 02713776T DK 02713776 T DK02713776 T DK 02713776T DK 1368094 T3 DK1368094 T3 DK 1368094T3
- Authority
- DK
- Denmark
- Prior art keywords
- methoxypyrid
- pyrazolo
- butylamino
- enantiomers
- triazine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27540301P | 2001-03-13 | 2001-03-13 | |
PCT/US2002/006837 WO2002072202A1 (fr) | 2001-03-13 | 2002-03-06 | 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, ses enantiomeres et sels pharmaceutiquement acceptables en tant que ligands du recepteur de la corticoliberine |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1368094T3 true DK1368094T3 (da) | 2007-07-02 |
Family
ID=23052141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02713776T DK1368094T3 (da) | 2001-03-13 | 2002-03-06 | 4-(2-Butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)-pyrazolo[1,5-a]-1,3,5-triazin, dens enantiomerer og farmaceutisk acceptable salte som corticotropin-frigivende faktor-receptor- ligander |
Country Status (36)
Country | Link |
---|---|
US (4) | US20030125330A1 (fr) |
EP (1) | EP1368094B1 (fr) |
JP (1) | JP4549630B2 (fr) |
KR (1) | KR100875595B1 (fr) |
CN (1) | CN100427093C (fr) |
AR (1) | AR032986A1 (fr) |
AT (1) | ATE355102T1 (fr) |
AU (1) | AU2002245605B2 (fr) |
BG (1) | BG66331B1 (fr) |
BR (1) | BR0208357A (fr) |
CA (1) | CA2440553C (fr) |
CY (1) | CY1106607T1 (fr) |
CZ (1) | CZ20032481A3 (fr) |
DE (1) | DE60218434T2 (fr) |
DK (1) | DK1368094T3 (fr) |
EE (1) | EE05433B1 (fr) |
ES (1) | ES2282401T3 (fr) |
GE (1) | GEP20053608B (fr) |
HK (1) | HK1057182A1 (fr) |
HR (1) | HRP20030822B1 (fr) |
HU (1) | HU229317B1 (fr) |
IL (2) | IL157615A0 (fr) |
IS (1) | IS2839B (fr) |
MX (1) | MXPA03008185A (fr) |
MY (1) | MY146935A (fr) |
NO (1) | NO328580B1 (fr) |
NZ (1) | NZ528207A (fr) |
PL (1) | PL208278B1 (fr) |
PT (1) | PT1368094E (fr) |
RS (1) | RS50863B (fr) |
RU (1) | RU2292347C2 (fr) |
SK (1) | SK287603B6 (fr) |
TW (1) | TWI257388B (fr) |
UA (1) | UA74634C2 (fr) |
WO (1) | WO2002072202A1 (fr) |
ZA (1) | ZA200306995B (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7094782B1 (en) * | 1996-07-24 | 2006-08-22 | Bristol-Myers Squibb Company | Azolo triazines and pyrimidines |
MXPA03008185A (es) * | 2001-03-13 | 2004-01-29 | Bristol Myers Squibb Pharma Co | 4-(2-butilamino)-2, 7-dimetil-8 -(2-metil-6-metoxipirid -3-il) pirazol-[1, 5-a]-1, 3, 5-triazina, sus enantiomeros y sales farmaceuticamente aceptables como ligandos del receptor del factor de liberacion de corticotropina. |
FR2842809A1 (fr) * | 2002-07-26 | 2004-01-30 | Greenpharma Sas | NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION |
AR041470A1 (es) | 2002-10-17 | 2005-05-18 | Upjohn Co | Compuestos de pirrolo (1,2 - b) piridazina y sus usos |
US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7041671B2 (en) * | 2003-04-02 | 2006-05-09 | Pfizer Inc | Pyrrolo[1,2-b]pyridazine compounds and their uses |
US7034023B2 (en) | 2003-04-04 | 2006-04-25 | Pfizer Inc | Pyrrolo[1,2-B]pyridazine compounds and their uses |
US7056920B2 (en) | 2003-04-04 | 2006-06-06 | Pfizer Inc | Pyrrolo[1,2-B]pyridazine compounds and their uses |
JP2006523675A (ja) * | 2003-04-15 | 2006-10-19 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | ピロロ[1,2−b]ピリダジン化合物及びそれらの使用 |
US7153961B2 (en) | 2003-11-25 | 2006-12-26 | Bristol-Myers Squibb Pharma Co. | Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist |
US7208596B2 (en) | 2003-11-25 | 2007-04-24 | Bristol-Myers Squibb Pharma Company | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof |
MX2009003125A (es) * | 2006-09-20 | 2009-05-28 | Lilly Co Eli | Tiazol pirazolopirimidinas como antagonistas de receptor de crf1. |
US20150094310A1 (en) * | 2012-04-23 | 2015-04-02 | Holsboermaschmeyer Neurochemie Gmbh | Crhr1 antagonists for use in the treatment of patients having crh overactivity |
GB201210686D0 (en) | 2012-06-15 | 2012-08-01 | Holsboermaschmeyer Neurochemie Gmbh | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
GB201310782D0 (en) | 2013-06-17 | 2013-07-31 | Max Planck Innovation Gmbh | Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms |
KR102079844B1 (ko) | 2016-09-20 | 2020-02-20 | 가톨릭대학교 산학협력단 | 담석 용해제를 포함하는 담낭 질환 치료용 약학 조성물 |
CN116322544A (zh) | 2020-08-12 | 2023-06-23 | 云杉生物科学公司 | 用于治疗多囊卵巢综合征的方法和组合物 |
US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW444018B (en) | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
CN1142817A (zh) | 1993-10-12 | 1997-02-12 | 杜邦麦克制药有限公司 | 1n-烷基-n-芳基嘧啶胺及其衍生物 |
TW530047B (en) | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
CA2249598A1 (fr) | 1996-03-26 | 1997-10-02 | Paul Joseph Gilligan | Pyridines et pyrimidines a fusion aryloxy et arylthio et derives de ces dernieres |
US6107300A (en) | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
AU3064397A (en) | 1996-05-24 | 1997-12-09 | Dow Chemical Company, The | Process for preparing aliphatic ester compounds and alkanols |
EA006626B1 (ru) | 1996-07-24 | 2006-02-24 | Дюпон Фармасьютикалз Компани | Азолопиримидины, фармацевтическая композиция и способ лечения |
US6191131B1 (en) * | 1997-07-23 | 2001-02-20 | Dupont Pharmaceuticals Company | Azolo triazines and pyrimidines |
SI9720045B (sl) * | 1996-07-24 | 2008-02-29 | Bristol Myers Squibb Pharma Co | Azolo triazini in pirimidini |
HUP9903965A3 (en) * | 1996-08-28 | 2002-02-28 | Pfizer | Substituted 6,5-hetero-bicyclic derivatives |
UA62972C2 (en) | 1997-07-03 | 2004-01-15 | Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders | |
US6103737A (en) | 1997-07-03 | 2000-08-15 | Dupont Pharmaceuticals Company | Aryl- and arylamino- substituted heterocycles as corticotropin releasing hormone antagonists |
WO1999001454A1 (fr) | 1997-07-03 | 1999-01-14 | Du Pont Pharmaceuticals Company | Imidazopyrimidines et imidazopyridines utiles pour traiter des troubles neurologiques |
ATE221886T1 (de) | 1997-09-02 | 2002-08-15 | Bristol Myers Squibb Pharma Co | Heterocyclyl-substituierte annellierte pyridine und pyrimidine als antagonisten des corticotropin freisetzenden hormons (crh), verwendbar für die behandlung von cns und stress |
CN1137123C (zh) * | 1998-01-28 | 2004-02-04 | 杜邦药品公司 | 吡咯并三嗪和嘧啶化合物 |
US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
JP2002510695A (ja) | 1998-04-03 | 2002-04-09 | デュポン ファーマシューティカルズ カンパニー | 副腎皮質刺激ホルモン放出因子(CRF)拮抗剤としてのチアゾロ[4,5−d]ピリミジンおよびピリジン |
US6124463A (en) | 1998-07-02 | 2000-09-26 | Dupont Pharmaceuticals | Benzimidazoles as corticotropin release factor antagonists |
MXPA03008185A (es) * | 2001-03-13 | 2004-01-29 | Bristol Myers Squibb Pharma Co | 4-(2-butilamino)-2, 7-dimetil-8 -(2-metil-6-metoxipirid -3-il) pirazol-[1, 5-a]-1, 3, 5-triazina, sus enantiomeros y sales farmaceuticamente aceptables como ligandos del receptor del factor de liberacion de corticotropina. |
-
2002
- 2002-03-06 MX MXPA03008185A patent/MXPA03008185A/es active IP Right Grant
- 2002-03-06 CA CA2440553A patent/CA2440553C/fr not_active Expired - Fee Related
- 2002-03-06 BR BR0208357-4A patent/BR0208357A/pt active Search and Examination
- 2002-03-06 ES ES02713776T patent/ES2282401T3/es not_active Expired - Lifetime
- 2002-03-06 PL PL368644A patent/PL208278B1/pl unknown
- 2002-03-06 JP JP2002571157A patent/JP4549630B2/ja not_active Expired - Fee Related
- 2002-03-06 AU AU2002245605A patent/AU2002245605B2/en not_active Ceased
- 2002-03-06 IL IL15761502A patent/IL157615A0/xx unknown
- 2002-03-06 GE GE5322A patent/GEP20053608B/en unknown
- 2002-03-06 AT AT02713776T patent/ATE355102T1/de active
- 2002-03-06 RU RU2003130093/04A patent/RU2292347C2/ru not_active IP Right Cessation
- 2002-03-06 EP EP02713776A patent/EP1368094B1/fr not_active Expired - Lifetime
- 2002-03-06 NZ NZ528207A patent/NZ528207A/en not_active IP Right Cessation
- 2002-03-06 US US10/092,312 patent/US20030125330A1/en not_active Abandoned
- 2002-03-06 SK SK1157-2003A patent/SK287603B6/sk not_active IP Right Cessation
- 2002-03-06 CN CNB028064151A patent/CN100427093C/zh not_active Expired - Fee Related
- 2002-03-06 DE DE60218434T patent/DE60218434T2/de not_active Expired - Lifetime
- 2002-03-06 HU HU0303480A patent/HU229317B1/hu not_active IP Right Cessation
- 2002-03-06 RS YUP-715/03A patent/RS50863B/sr unknown
- 2002-03-06 EE EEP200300435A patent/EE05433B1/xx not_active IP Right Cessation
- 2002-03-06 KR KR1020037011913A patent/KR100875595B1/ko not_active IP Right Cessation
- 2002-03-06 CZ CZ20032481A patent/CZ20032481A3/cs unknown
- 2002-03-06 PT PT02713776T patent/PT1368094E/pt unknown
- 2002-03-06 WO PCT/US2002/006837 patent/WO2002072202A1/fr active IP Right Grant
- 2002-03-06 DK DK02713776T patent/DK1368094T3/da active
- 2002-03-12 MY MYPI20020879A patent/MY146935A/en unknown
- 2002-03-13 AR ARP020100908A patent/AR032986A1/es not_active Application Discontinuation
- 2002-03-13 TW TW091104706A patent/TWI257388B/zh not_active IP Right Cessation
- 2002-06-03 UA UA2003109244A patent/UA74634C2/uk unknown
-
2003
- 2003-02-05 US US10/358,652 patent/US7157578B2/en not_active Expired - Lifetime
- 2003-08-27 IL IL157615A patent/IL157615A/en not_active IP Right Cessation
- 2003-09-08 ZA ZA200306995A patent/ZA200306995B/en unknown
- 2003-09-10 IS IS6947A patent/IS2839B/is unknown
- 2003-09-11 NO NO20034023A patent/NO328580B1/no not_active IP Right Cessation
- 2003-09-23 BG BG108189A patent/BG66331B1/bg unknown
- 2003-10-10 HR HR20030822A patent/HRP20030822B1/xx not_active IP Right Cessation
-
2004
- 2004-01-02 HK HK04100028A patent/HK1057182A1/xx not_active IP Right Cessation
-
2006
- 2006-11-07 US US11/593,715 patent/US7358252B2/en not_active Expired - Lifetime
-
2007
- 2007-05-18 CY CY20071100678T patent/CY1106607T1/el unknown
-
2008
- 2008-02-13 US US12/030,439 patent/US7662817B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1368094T3 (da) | 4-(2-Butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)-pyrazolo[1,5-a]-1,3,5-triazin, dens enantiomerer og farmaceutisk acceptable salte som corticotropin-frigivende faktor-receptor- ligander | |
DK1235830T3 (da) | Pyrrolo[2,3-d]pyrimidin-forbindelser som proteinkinaseinhibitorer | |
NO20021356D0 (no) | Alkylendiamin-substituerte pyrazolo[1,5,-a]-1,5-pyrimidiner og pyrazolo[1,5-a]-1,3,5-triaziner | |
ATE388713T1 (de) | 4-amino-6-phenyl-pyrrolo(2,3-d)pyrimidin derivate | |
NO20053955D0 (no) | Pyrazolo [1,5-A] pyrimidinderivater | |
ATE284404T1 (de) | Pyrazolo(4,3-d)pyrimidinderivate | |
AU2004209447A8 (en) | Pyrazolo`1,5-a!`1,3,5!triazine derivatives as cannabinoid receptor ligands | |
DE60203917D1 (de) | Phenylsulfonyl-1,3-dihydro-2h-indol-2-on derivate, deren herstellung und deren therapeutische verwendung | |
DK1397351T3 (da) | Pyrimidin-, triazin- og pyrazinderivater som glutamatreceptorer | |
ZA200306341B (en) | Imidazo (1,2-a)-pyridine derivatives as mGluR5 antagonists. | |
NO20012725L (no) | Nye triazolo(4,5-D)pyrimidinforbindelser | |
DK1430056T3 (da) | Substituerede 2-pyrimidinyl - 6,7,8,9-tetrahydropyrimido-[1,2-a]pyrimidin-4-on- og 7-pyrimidinyl-2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) onderivater mod neurodegenerative lidelser | |
WO2002036123A3 (fr) | Nouveaux traitements destines au syndrome des jambes sans repos | |
DE60205921D1 (de) | SUBSTITUIERTE 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDOç1,2-A!PYRIMIDIN-4-ON- UND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO-ç1,2-A!PYRIMIDIN-5(1H)ONDERIVATE | |
DE60005690D1 (de) | Titanverbindungen, deren herstellung und verwendung | |
DE60302220D1 (de) | 1-(alkyl), 1-(heteroaryl)alkyl und 1-[aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(h)-one derivate | |
SI1560830T1 (sl) | Derivati (6,7-dihidro-5H-imidazo(1,2-alfa)imidazol-3-sulfonilamino)-propionamida in njihova uporaba kot inhibitorji interakcije CAM in levkointegrinov | |
NO20041178L (no) | Fremgangsmate for fremstilling av 6-(4-klorfenyl)-2,2-dimetyl-7-fenyl-2,3-dihydro-1H-pyrrolizin-5-yl-eddiksyre | |
ATE294180T1 (de) | Substituierte 3,4-dihydro-pyrimido (1,2- a)pyrimidine und 3,4-dihydropyrazino (1,2- a)pyrimidine | |
AR028349A1 (es) | Proceso para preparar rcido 6-(4-clorofenil)-2,2 dimetil-7-fenil-2,3-dihidro-1h-pirrolizin-5-ilacético | |
ITMI20011735A0 (it) | Procedimento per la preparazione del 14beta-idrossi-baccatina iii-1,14-carbonato | |
ITMI20011731A0 (it) | Oricedimento per la preparazione del \4beta-idrosasi-baccatina iii-1,14-carbonato |